A Phase 2 interventional study of Nivolumab and Dasatinib in Advanced Cancer, sponsored by Bristol-Myers Squibb. Terminated at 50 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-22.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator
Biological: Nivolumab
Nivolumab in combination with Dasatinib
Biological: Nivolumab · Drug: Dasatinib
Nivolumab in combination with Relatlimab
Biological: Nivolumab · Biological: Relatlimab
Nivolumab in combination with Ipilimumab
Biological: Nivolumab · Biological: Ipilimumab
Nivolumab in combination with BMS- 986205
Biological: Nivolumab · Drug: BMS-986205
Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
Also known as: BMS-936558, MDX-1106, OPDIVO
Also known as: BMS-354825, SPRYCEL
Also known as: BMS-986016
Also known as: BMS-734016, Yervoy
Specified dose on specified days
Objective Response Rate (ORR)
ORR is defined as the percentage of participants whose confirmed best overall response (BOR) is either a complete response (CR) or partial response (PR). BOR was assessed by investigator per RECIST1.1. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3). Results for each study track are presented only for treatment groups who received a treatment in that specific track.
Time frame: From first dose to 2 years following last dose (up to 30 months)
Duration of Response (DOR)
DOR, computed for all treated participants with a confirmed BOR of CR or PR, is defined as the time between the date of first response and the date of first documented disease progression (as determined by RECIST 1.1) or death due to any cause. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3). Results for each study track are presented only for treatment groups who received a treatment in that specific track.
Time frame: From first dose to 2 years following last dose (up to 30 months)
Progression Free Survival Rate (PFSR) at 24 Weeks
The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive (\>=1%) Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative (\<1%) Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3). Results for each study track are presented only for treatment groups who received a treatment in that specific track.
Time frame: From first dose to 24 weeks after first dose
Percentage of Participants Experiencing Adverse Events (AEs)
This outcome measure describes the percentage of participants who experienced any grade, all causality AEs during the specified time frame
Time frame: From first dose to 100 days following last dose
Percentage of Participants Experiencing Serious Adverse Events (SAEs)
This outcome measure describes the percentage of participants who experienced any grade, all causality SAEs during the specified time frame
Time frame: From first dose to 100 days following last dose
Percentage of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
This outcome measure describes the percentage of participants who experienced all causality AEs leading to discontinuation of study therapy during the specified time frame
Time frame: From first dose to 100 days following last dose
Percentage of Participants Experiencing Death
This outcome measure describes the percentage of participants who died (due to any cause) during the specified time frame
Time frame: From first dose to up to 45 months following first dose
Number of Participants Experiencing Laboratory Abnormalities in Hepatic Tests
The following measurements will be considered laboratory abnormalities for hepatic tests: * ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN * Total bilirubin \> 2 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN ALT=Alanine aminotransferase AST=Aspartate aminotransferase ULN=Upper Limit of Normal
Time frame: From first dose to 100 days following last dose (approximately 9 months)
Number of Participants Experiencing Laboratory Abnormalities in Thyroid Tests
The following measurements will be considered laboratory abnormalities for thyroid tests: * TSH value \> ULN and * With baseline TSH value ≤ ULN * At least one T3/T4 test value \< LLN * Low TSH \< LLN and * With baseline TSH value ≥ LLN * At least one T3/T4 test value \> ULN TSH = thyroid stimulating hormone ULN=Upper Limit of Normal LLN=Lower Limit of Normal T3=Triiodothyronine T4=Thyroxine
Time frame: From first dose to 100 days following last dose (approximately 9 months)
| Milestone | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| Started | 40 | 4 | 0 | 3 | 0 |
| Completed | 13 | 2 | 0 | 1 | 0 |
| Not completed | 27 | 2 | 0 | 2 | 0 |
| Withdrew: Disease progression | 20 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event unrelated to study drug | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Study drug toxicity | 4 | 1 | 0 | 1 | 0 |
| Withdrew: Participant request to discontinue | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other reasons | 1 | 0 | 0 | 0 | 0 |
| Milestone | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| Started | 9 | 8 | 2 | 12 | 0 |
| Completed | 3 | 0 | 0 | 5 | 0 |
| Not completed | 6 | 8 | 2 | 7 | 0 |
| Withdrew: Disease progression | 4 | 5 | 2 | 5 | 0 |
| Withdrew: Adverse event unrelated to study drug | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Study drug toxicity | 1 | 2 | 0 | 2 | 0 |
| Withdrew: Participant withdrew consent | 0 | 1 | 0 | 0 | 0 |
| Milestone | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| Started | 0 | 41 | 16 | 18 | 0 |
| Completed | 0 | 5 | 1 | 2 | 0 |
| Not completed | 0 | 36 | 15 | 16 | 0 |
| Withdrew: Disease progression | 0 | 24 | 13 | 14 | 0 |
| Withdrew: Adverse event unrelated to study drug | 0 | 1 | 1 | 1 | 0 |
| Withdrew: Study drug toxicity | 0 | 3 | 0 | 1 | 0 |
| Withdrew: Participant request to discontinue | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Participant withdrew consent | 0 | 3 | 1 | 0 | 0 |
| Withdrew: Other reasons | 0 | 3 | 0 | 0 | 0 |
| Milestone | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| Started | 0 | 53 | 0 | 60 | 0 |
| Completed | 0 | 2 | 0 | 18 | 0 |
| Not completed | 0 | 51 | 0 | 42 | 0 |
| Withdrew: Study drug toxicity | 0 | 6 | 0 | 5 | 0 |
| Withdrew: Participant request to discontinue | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Participant withdrew consent | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other reasons | 0 | 5 | 0 | 3 | 0 |
| Withdrew: Disease progression | 0 | 33 | 0 | 32 | 0 |
| Withdrew: Adverse event unrelated to study drug | 0 | 5 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 |
| Milestone | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 43 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 43 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 34 |
| Withdrew: Adverse event unrelated to study drug | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Study drug toxicity | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Participant request to discontinue | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 2 |
ORR is defined as the percentage of participants whose confirmed best overall response (BOR) is either a complete response (CR) or partial response (PR). BOR was assessed by investigator per RECIST1.1. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3). Results for each study track are presented only for treatment groups who received a treatment in that specific track.
| Percent of Participants | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| Study Track 1 | 17.5 (7.3 to 32.8) | 25.0 (0.6 to 80.6) | — | 0 (0.0 to 70.8) | — |
| Study Track 2 | 0 (0.0 to 33.6) | 0 (0.0 to 33.6) | 0 (0.0 to 84.2) | 25.0 (5.5 to 57.2) | — |
| Study Track 3 | — | 2.4 (0.1 to 12.9) | 0 (0.0 to 20.6) | 5.6 (0.1 to 27.3) | — |
| Study Track 4 | — | 1.9 (0.0 to 10.1) | — | 20.0 (10.8 to 32.3) | — |
| Study Track 5 | — | — | — | — | 2.3 (0.1 to 12.3) |
DOR, computed for all treated participants with a confirmed BOR of CR or PR, is defined as the time between the date of first response and the date of first documented disease progression (as determined by RECIST 1.1) or death due to any cause. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3). Results for each study track are presented only for treatment groups who received a treatment in that specific track.
| Months | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| Study Track 1 | 12.81 (0.0 to NA) | 8.57 (NA to NA) | — | — | — |
| Study Track 2 | — | — | — | NA (NA to NA) | — |
| Study Track 3 | — | NA (NA to NA) | — | NA (NA to NA) | — |
| Study Track 4 | — | NA (NA to NA) | — | 12.65 (8.7 to NA) | — |
| Study Track 5 | — | — | — | — | 3.75 (NA to NA) |
The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Results are presented by study track. Track 1 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 positive (\>=1%) Track 2 = participants naive for prior immuno-oncology (IO) therapy and PD-L1 negative (\<1%) Track 3 = participants with prior anti-PD-1/PD-L1 therapy Track 4 = participants naive for prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3) Track 5 = participants with prior anti-PD-1/PD-L1 therapy (established upon enrollment closure of tracks 1,2 and 3). Results for each study track are presented only for treatment groups who received a treatment in that specific track.
| Proportion of Participants | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| Study Track 1 | 0.302 (0.164 to 0.451) | NA (NA to NA) | — | NA (NA to NA) | — |
| Study Track 2 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 0.455 (0.167 to 0.707) | — |
| Study Track 3 | — | 0.191 (0.079 to 0.340) | NA (NA to NA) | NA (NA to NA) | — |
| Study Track 4 | — | NA (NA to NA) | — | 0.391 (0.265 to 0.514) | — |
| Study Track 5 | — | — | — | — | 0.111 (0.036 to 0.235) |
This outcome measure describes the percentage of participants who experienced any grade, all causality AEs during the specified time frame
| Percent of Participants | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Adverse Events (AEs) | 100.0 | 100.0 | 100.0 | 98.9 | 100.0 |
This outcome measure describes the percentage of participants who experienced any grade, all causality SAEs during the specified time frame
| Percent of Participants | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Serious Adverse Events (SAEs) | 57.1 | 53.8 | 61.1 | 58.1 | 60.5 |
This outcome measure describes the percentage of participants who experienced all causality AEs leading to discontinuation of study therapy during the specified time frame
| Percent of Participants | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 14.3 | 23.6 | 5.6 | 11.8 | 14.0 |
This outcome measure describes the percentage of participants who died (due to any cause) during the specified time frame
| Percent of Participants | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Death | 57.1 | 55.7 | 66.7 | 46.2 | 62.8 |
The following measurements will be considered laboratory abnormalities for hepatic tests: * ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN * Total bilirubin \> 2 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN ALT=Alanine aminotransferase AST=Aspartate aminotransferase ULN=Upper Limit of Normal
| Participants | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| ALT OR AST > 3XULN | 4 | 3 | 1 | 5 | 3 |
| ALT OR AST > 5XULN | 2 | 0 | 0 | 3 | 2 |
| ALT OR AST > 10XULN | 2 | 0 | 0 | 1 | 2 |
| ALT OR AST > 20XULN | 0 | 0 | 0 | 1 | 1 |
| TOTAL BILIRUBIN > 2XULN | 1 | 0 | 0 | 2 | 3 |
| Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN | 0 | 0 | 0 | 2 | 2 |
| Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN | 0 | 0 | 0 | 2 | 2 |
The following measurements will be considered laboratory abnormalities for thyroid tests: * TSH value \> ULN and * With baseline TSH value ≤ ULN * At least one T3/T4 test value \< LLN * Low TSH \< LLN and * With baseline TSH value ≥ LLN * At least one T3/T4 test value \> ULN TSH = thyroid stimulating hormone ULN=Upper Limit of Normal LLN=Lower Limit of Normal T3=Triiodothyronine T4=Thyroxine
| Participants | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 |
|---|---|---|---|---|---|
| TSH > ULN | 9 | 16 | 3 | 24 | 9 |
| TSH > ULN WITH TSH <= ULN AT BASELINE | 6 | 9 | 1 | 17 | 6 |
| TSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN | 4 | 3 | 1 | 8 | 6 |
| TSH < LLN | 5 | 3 | 0 | 20 | 4 |
| TSH < LLN WITH TSH >= LLN AT BASELINE | 5 | 1 | 0 | 16 | 4 |
| TSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN | 3 | 1 | 0 | 5 | 0 |
Collected over All cause mortality: from first dose to up to 45 months after first dose SAEs and AEs: from first dose to 100 days following last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Track 1 - Nivolumab | 22/40 (55%) | 24/40 (60%) | 38/40 (95%) |
| Track 1 - Nivolumab + Dasatinib | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| Track 1 - Nivolumab + Ipilimumab | 1/3 (33.3%) | 0/3 (0%) | 3/3 (100%) |
| Track 2 - Nivolumab | 6/9 (66.7%) | 4/9 (44.4%) | 9/9 (100%) |
| Track 2 - Nivolumab + Dasatinib | 4/8 (50%) | 5/8 (62.5%) | 7/8 (87.5%) |
| Track 2 - Nivolumab + BMS986016 | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) |
| Track 2 - Nivolumab + Ipilimumab | 6/12 (50%) | 5/12 (41.7%) | 12/12 (100%) |
| Track 3 - Nivolumab + Dasatinib | 20/41 (48.8%) | 17/41 (41.5%) | 38/41 (92.7%) |
| Track 3 - Nivolumab + BMS986016 | 10/16 (62.5%) | 9/16 (56.3%) | 16/16 (100%) |
| Track 3 - Nivolumab + Ipilimumab | 9/18 (50%) | 10/18 (55.6%) | 17/18 (94.4%) |
| Track 4 - Nivolumab + Dasatinib | 33/53 (62.3%) | 33/53 (62.3%) | 50/53 (94.3%) |
| Track 4 - Nivolumab + Ipilimumab | 27/60 (45%) | 39/60 (65%) | 59/60 (98.3%) |
| Track 5 - Nivolumab + BMS986205 | 27/43 (62.8%) | 26/43 (60.5%) | 41/43 (95.3%) |
| Event | Track 1 - Nivolumab | Track 1 - Nivolumab + Dasatinib | Track 1 - Nivolumab + Ipilimumab | Track 2 - Nivolumab | Track 2 - Nivolumab + Dasatinib | Track 2 - Nivolumab + BMS986016 | Track 2 - Nivolumab + Ipilimumab | Track 3 - Nivolumab + Dasatinib | Track 3 - Nivolumab + BMS986016 | Track 3 - Nivolumab + Ipilimumab | Track 4 - Nivolumab + Dasatinib | Track 4 - Nivolumab + Ipilimumab | Track 5 - Nivolumab + BMS986205 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Atrial flutterCardiac disorders | 0/40 | 0/4 | 0/3 | 0/9 | 0/8 | 1/2 | 0/12 | 0/41 | 0/16 | 0/18 | 0/53 | 1/60 | 0/43 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/40 | 0/4 | 0/3 | 2/9 | 1/8 | 1/2 | 1/12 | 9/41 | 3/16 | 3/18 | 19/53 | 16/60 | 13/43 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 3/40 | 0/4 | 0/3 | 0/9 | 1/8 | 1/2 | 0/12 | 1/41 | 0/16 | 0/18 | 4/53 | 3/60 | 3/43 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/40 | 0/4 | 0/3 | 0/9 | 0/8 | 1/2 | 0/12 | 0/41 | 0/16 | 0/18 | 0/53 | 1/60 | 1/43 |
| Pericardial effusionCardiac disorders | 3/40 | 1/4 | 0/3 | 0/9 | 0/8 | 0/2 | 0/12 | 0/41 | 0/16 | 0/18 | 0/53 | 1/60 | 0/43 |
| PyrexiaGeneral disorders | 0/40 | 1/4 | 0/3 | 0/9 | 0/8 | 0/2 | 0/12 | 0/41 | 0/16 | 0/18 | 2/53 | 3/60 | 0/43 |
| PneumoniaInfections and infestations | 2/40 | 1/4 | 0/3 | 1/9 | 0/8 | 0/2 | 0/12 | 1/41 | 0/16 | 2/18 | 0/53 | 3/60 | 1/43 |
| Post procedural infectionInfections and infestations | 0/40 | 1/4 | 0/3 | 0/9 | 0/8 | 0/2 | 0/12 | 0/41 | 0/16 | 0/18 | 0/53 | 0/60 | 0/43 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/40 | 1/4 | 0/3 | 0/9 | 2/8 | 0/2 | 0/12 | 1/41 | 0/16 | 1/18 | 3/53 | 2/60 | 1/43 |
| Oesophageal food impactionGastrointestinal disorders | 0/40 | 0/4 | 0/3 | 0/9 | 1/8 | 0/2 | 0/12 | 0/41 | 0/16 | 0/18 | 0/53 | 0/60 | 0/43 |
| Event | Track 1 - Nivolumab | Track 1 - Nivolumab + Dasatinib | Track 1 - Nivolumab + Ipilimumab | Track 2 - Nivolumab | Track 2 - Nivolumab + Dasatinib | Track 2 - Nivolumab + BMS986016 | Track 2 - Nivolumab + Ipilimumab | Track 3 - Nivolumab + Dasatinib | Track 3 - Nivolumab + BMS986016 | Track 3 - Nivolumab + Ipilimumab | Track 4 - Nivolumab + Dasatinib | Track 4 - Nivolumab + Ipilimumab | Track 5 - Nivolumab + BMS986205 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 9/40 | 3/4 | 3/3 | 0/9 | 1/8 | 0/2 | 3/12 | 9/41 | 1/16 | 2/18 | 20/53 | 18/60 | 13/43 |
| NauseaGastrointestinal disorders | 14/40 | 3/4 | 2/3 | 3/9 | 4/8 | 0/2 | 3/12 | 16/41 | 3/16 | 4/18 | 22/53 | 18/60 | 16/43 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 14/40 | 3/4 | 0/3 | 2/9 | 3/8 | 1/2 | 1/12 | 7/41 | 0/16 | 6/18 | 21/53 | 20/60 | 6/43 |
| RashSkin and subcutaneous tissue disorders | 5/40 | 1/4 | 2/3 | 0/9 | 2/8 | 0/2 | 0/12 | 7/41 | 3/16 | 3/18 | 7/53 | 10/60 | 3/43 |
| FatigueGeneral disorders | 16/40 | 1/4 | 0/3 | 1/9 | 4/8 | 0/2 | 6/12 | 19/41 | 5/16 | 8/18 | 27/53 | 30/60 | 20/43 |
| DiarrhoeaGastrointestinal disorders | 13/40 | 0/4 | 1/3 | 2/9 | 4/8 | 0/2 | 4/12 | 8/41 | 5/16 | 2/18 | 20/53 | 17/60 | 11/43 |
| AstheniaGeneral disorders | 5/40 | 2/4 | 0/3 | 2/9 | 1/8 | 0/2 | 0/12 | 4/41 | 0/16 | 0/18 | 11/53 | 11/60 | 1/43 |
| Chest painGeneral disorders | 3/40 | 1/4 | 0/3 | 1/9 | 1/8 | 1/2 | 0/12 | 0/41 | 0/16 | 2/18 | 5/53 | 3/60 | 2/43 |
| OedemaGeneral disorders | 0/40 | 2/4 | 0/3 | 0/9 | 0/8 | 0/2 | 0/12 | 1/41 | 0/16 | 0/18 | 4/53 | 1/60 | 2/43 |
| PyrexiaGeneral disorders | 3/40 | 2/4 | 0/3 | 1/9 | 2/8 | 0/2 | 2/12 | 4/41 | 1/16 | 3/18 | 10/53 | 10/60 | 5/43 |
| Age, Continuous(Years) | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 | Total |
|---|---|---|---|---|---|---|
| Mean | 64.5 ± 10.27 | 63.6 ± 9.25 | 66.6 ± 9.17 | 62.3 ± 9.04 | 63.6 ± 7.89 | 63.5 ± 9.21 |
| Sex: Female, Male(Participants) | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 | Total |
|---|---|---|---|---|---|---|
| Female | 21 | 34 | 8 | 38 | 21 | 122 |
| Male | 28 | 70 | 9 | 50 | 16 | 173 |
| Ethnicity (NIH/OMB)(Participants) | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 0 | 5 | 1 | 9 |
| Not Hispanic or Latino | 25 | 65 | 17 | 58 | 27 | 192 |
| Unknown or Not Reported | 23 | 37 | 0 | 25 | 9 | 94 |
| Race (NIH/OMB)(Participants) | Nivolumab | Nivolumab + Dasatinib | Nivolumab + BMS986016 | Nivolumab + Ipilimumab | Nivolumab + BMS986205 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 7 | 2 | 2 | 3 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 6 | 1 | 6 | 6 | 19 |
| White | 42 | 85 | 14 | 78 | 26 | 245 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 6 | 0 | 2 | 2 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Jan 2020, 44 months.
Results were first posted in Mar 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dasatinib · Relatlimab · Ipilimumab · Linrodostat